A team of researchers from NCATS and the Icahn School of Medicine at Mount Sinai identified more than 50 drugs that may block Ebola virus-like particles from entering and infecting cells.
An assay (test) developed at NCATS helped a research team identify a potential new drug target to treat a neurological disorder, called Charcot-Marie-Tooth disease.
Bridging Interventional Development Gaps researchers will support two projects aimed at finding treatments for diabetic keratopathy — a condition that often leads to blindness — and severe heart attacks.
NCATS researchers will begin work on three new pre-clinical drug development projects for malaria, Lassa fever and two blood disorders through the Therapeutics for Rare and Neglected Diseases program.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
Rare Diseases Clinical Research Network expands to 22 consortia and a data center.
Eleven institutions will refine 3-D human tissue chips to test the safety of drugs.
- Notice of Clarification Regarding Clinical Trial Documentation Requirements for New Therapeutic Uses Investigators
- Notice To Extend PA-14-071 "PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications"
- Notice To Extend PA-14-072 "PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])"
- More Funding & Notices...
- Providers' Perspectives on Male Involvement in Family Planning in the Context of a Cluster-Randomized Controlled Trial • AIDS Care
- Study Identifies 53 Approved Drugs That May Block Ebola infection • Infection Control Today
- OmniCarb Study: Cutting Carbs No Silver Bullet • MedPage Today
- More News & Events...
IN THE SPOTLIGHT
Save the date for Rare Disease Day at NIH.